Introducing the AAV Complement Activation Assay

A New Standard in Safety Assessment for Gene Therapies

In AAV gene therapy, safety isn't optional-it's everything. That's why we're proud to introduce a powerful new tool to your immunogenicity toolkit: the AAV Complement Activation Assay.

This assay is the first of its kind available on the market, giving you a critical edge in detecting and managing immune responses that could compromise patient safety and therapeutic success.

Why Complement Activation Matter

While neutralizing and total antibodies have long been the focus of immunogenicity testing, complement activation is an emerging risk factor-and one that's gaining attention from regulators and clinicians alike.

Unchecked complement activation can lead to serious adverse events, including inflammation and tissue damage. Our assay helps you:

• Detect predisposition to AAV-mediated complement activation
• Reduce the risk of immune-related complications
• Strengthen your safety profile for regulatory review

What Makes Our Assay Different

Our Complement Activation Assay is currently offered exclusively through our CRO services, including:

• Assay development & customization, and subsequent sample analysis
• Scientific consultation and data interpretation
• Integration with our full immunogenicity panel (NAb + TAb)

Off-the-shelf kits are in development and will be available soon, but you can start benefiting from this assay today through our expert team.